Novavax, Inc.
NVAX
$8.05
-$0.09-1.11%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 413.80M | 596.34M | 1.12B | 1.06B | 1.08B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 413.80M | 596.34M | 1.12B | 1.06B | 1.08B |
| Cost of Revenue | 424.38M | 432.38M | 409.86M | 452.90M | 482.73M |
| Gross Profit | -10.58M | 163.96M | 713.62M | 611.75M | 595.99M |
| SG&A Expenses | 108.70M | 126.76M | 150.38M | 194.93M | 229.61M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 533.08M | 559.14M | 560.24M | 647.83M | 712.33M |
| Operating Income | -119.28M | 37.20M | 563.24M | 416.82M | 366.39M |
| Income Before Tax | -245.32M | -86.19M | 442.17M | 350.68M | 431.39M |
| Income Tax Expenses | 2.42M | 1.65M | 1.87M | 8.94M | 8.56M |
| Earnings from Continuing Operations | -247.73 | -87.84 | 440.30 | 341.75 | 422.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -247.73M | -87.84M | 440.30M | 341.75M | 422.82M |
| EBIT | -119.28M | 37.20M | 563.24M | 416.82M | 366.39M |
| EBITDA | -101.45M | 59.53M | 590.85M | 451.83M | 407.51M |
| EPS Basic | -1.52 | -0.54 | 2.74 | 2.13 | 2.61 |
| Normalized Basic EPS | -0.37 | 0.24 | 2.27 | 1.69 | 1.52 |
| EPS Diluted | -1.52 | -0.58 | 2.41 | 1.79 | 2.28 |
| Normalized Diluted EPS | -0.37 | 0.20 | 2.05 | 1.47 | 1.30 |
| Average Basic Shares Outstanding | 652.73M | 650.18M | 647.95M | 645.66M | 643.36M |
| Average Diluted Shares Outstanding | 655.39M | 668.03M | 682.38M | 677.43M | 675.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |